

Weijian Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/227173/publications.pdf>

Version: 2024-02-01

79
papers

2,021
citations

430874

18
h-index

265206

42
g-index

79
all docs

79
docs citations

79
times ranked

2964
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2: a novel target for cancer treatment. <i>Journal of Hematology and Oncology</i> , 2020, 13, 104.	17.0	447
2	Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. <i>Biomarker Research</i> , 2018, 6, 10.	6.8	276
3	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	7.4	202
4	The polycomb group protein EZH2 induces epithelialâ€“mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. <i>Journal of Hematology and Oncology</i> , 2018, 11, 9.	17.0	94
5	Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. <i>Oncotarget</i> , 2016, 7, 9815-9831.	1.8	90
6	<i>MUC4</i> , <i>MUC16</i> , and <i>TTN</i> genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e155.	4.0	80
7	Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 9052-9063.	2.8	77
8	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. <i>Oncotarget</i> , 2015, 6, 24448-24462.	1.8	76
9	Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. <i>Human Immunology</i> , 2014, 75, 1128-1137.	2.4	55
10	Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. <i>Journal of Hematology and Oncology</i> , 2016, 9, 90.	17.0	53
11	Subcutaneous envafolelimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 95.	17.0	50
12	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1603-1610.	7.0	37
13	The influence of marital status on the stage at diagnosis, treatment, and survival of adult patients with gastric cancer: a population-based study. <i>Oncotarget</i> , 2017, 8, 22385-22405.	1.8	37
14	Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. <i>Carcinogenesis</i> , 2017, 38, 837-846.	2.8	30
15	Protocadherinâ€“8 promotes invasion and metastasis via laminin subunit Î²2 in gastric cancer. <i>Cancer Science</i> , 2018, 109, 732-740.	3.9	30
16	Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. <i>Oncotarget</i> , 2017, 8, 35783-35791.	1.8	29
17	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e116027.	2.5	22
18	Development and validation of nomograms for prediction of overall survival and cancer-specific survival of patients with Stage IV colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 438-446.	1.3	22

#	ARTICLE	IF	CITATIONS
19	TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy. <i>Aging</i> , 2020, 12, 14556-14568.	3.1	20
20	MiR-486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro. <i>Cancer Medicine</i> , 2018, 7, 4627-4638.	2.8	17
21	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. <i>Oncotarget</i> , 2015, 6, 39018-39027.	1.8	17
22	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015, 6, 40519-40534.	1.8	16
23	The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China. <i>Journal of Cancer</i> , 2018, 9, 1188-1199.	2.5	16
24	BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 355-361.	2.0	14
25	Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy. <i>Journal of Cancer</i> , 2020, 11, 3310-3317.	2.5	13
26	VPS52 induces apoptosis via cathepsin D in gastric cancer. <i>Journal of Molecular Medicine</i> , 2017, 95, 1107-1116.	3.9	12
27	Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases. <i>European Journal of Radiology</i> , 2020, 130, 109149.	2.6	12
28	Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV)-mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. <i>Oncotarget</i> , 2016, 7, 22733-22745.	1.8	12
29	Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. <i>Oncotarget</i> , 2017, 8, 37826-37834.	1.8	11
30	Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. <i>Tumor Biology</i> , 2016, 37, 1753-1762.	1.8	9
31	Predictive model for risk of gastric cancer using genetic variants from genome-wide association studies and high-evidence meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 7310-7316.	2.8	9
32	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 547-557.	2.0	9
33	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	3.2	9
34	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. <i>BMC Cancer</i> , 2017, 17, 188.	2.6	8
35	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	2.9	8
36	<p>Microsatellite Instability-Related ACVR2A Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3809-3821.	2.0	8

#	ARTICLE	IF	CITATIONS
37	miR-345 inhibits migration and stem-like cell phenotype in gastric cancer via inactivation of Rac1 by targeting EPS8. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 259-267.	2.0	8
38	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 128-128.	1.6	7
39	Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer. <i>Cell Death and Disease</i> , 2022, 13, 392.	6.3	7
40	MicroRNA expression profiles of granulocytic myeloid-derived suppressor cells from mice bearing Lewis lung carcinoma. <i>Molecular Medicine Reports</i> , 2016, 14, 4567-4574.	2.4	6
41	Functional variant of <i>MTOR</i> rs2536 and survival of Chinese gastric cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 251-262.	5.1	5
42	Development and validation of nomograms for prediction of overall survival and cancer-specific survival of patients of colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 261-269.	1.3	5
43	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESKO, a randomized, double-blind, Phase III trial. <i>Future Oncology</i> , 2021, 17, 1339-1350.	2.4	5
44	A prospective phase II study of raltitrexed combined with S1 as salvage treatment for patients with refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 513-521.	1.1	4
45	AKP and GGT level can provide an early prediction of first-line treatment efficacy in colorectal cancer patients with hepatic metastases. <i>Biomarkers in Medicine</i> , 2021, 15, 697-713.	1.4	4
46	Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3521-3521.	1.6	3
47	FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4038-4038.	1.6	3
48	Envafolelimab (KN035) in advanced tumors with mismatch-repair deficiency.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3021-3021.	1.6	3
49	Integrin $\alpha_5\beta_1$ /Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells. <i>American Journal of Cancer Research</i> , 2020, 10, 2635-2648.	1.4	3
50	Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases. <i>Frontiers in Oncology</i> , 2022, 12, 747124.	2.8	3
51	Functional variation of SLC52A3 rs13042395 predicts survival of Chinese gastric cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12550-12559.	3.6	2
52	Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110390.	3.2	2
53	Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	2
54	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESKO trial. <i>Future Oncology</i> , 2021, 17, 1923-1931.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin,) Tj ETQq1 Journal of Clinical Oncology, 2021, 39, 4014-4014.	1.6	2
56	A retrospective study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.. Journal of Clinical Oncology, 2017, 35, e15066-e15066.	1.6	2
57	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. Journal of Clinical Oncology, 2019, 37, 4054-4054.	1.6	2
58	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.. Journal of Clinical Oncology, 2019, 37, e15012-e15012.	1.6	2
59	Angiotensin-converting enzyme insertion/deletion polymorphism and gastric cancer: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 5788-93.	1.3	2
60	A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.. Journal of Clinical Oncology, 2022, 40, 4062-4062.	1.6	2
61	Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. Oncology Letters, 2017, 15, 1334-1342.	1.8	1
62	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 4439-4450.	2.0	1
63	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 3537-3537.	1.6	1
64	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.. Journal of Clinical Oncology, 2018, 36, 3544-3544.	1.6	1
65	A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.. Journal of Clinical Oncology, 2018, 36, e15558-e15558.	1.6	1
66	A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.. Journal of Clinical Oncology, 2018, 36, e16084-e16084.	1.6	1
67	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial.. Journal of Clinical Oncology, 2020, 38, e16001-e16001.	1.6	1
68	Oncogenic alterations detected by droplet digital PCR in patients with metastatic colorectal cancer resistant to cetuximab.. Journal of Clinical Oncology, 2019, 37, 575-575.	1.6	1
69	Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. Oncology Letters, 2018, 16, 4489-4497.	1.8	0
70	Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer.. Journal of Clinical Oncology, 2021, 39, e16096-e16096.	1.6	0
71	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16037-e16037.	1.6	0
72	XELOX or mFOLFOX6 chemotherapy combined with resection of primary lesion versus chemotherapy alone for colon cancer with unresectable metastases: A randomized clinical trial.. Journal of Clinical Oncology, 2021, 39, 3590-3590.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16034-e16034.	1.6	0
74	Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.. Journal of Clinical Oncology, 2017, 35, 469-469.	1.6	0
75	Comparison of efficacy and safety of first-line palliative chemotherapy with TX and XELOX regimens in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. Journal of Clinical Oncology, 2017, 35, 4070-4070.	1.6	0
76	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.. Journal of Clinical Oncology, 2017, 35, 4052-4052.	1.6	0
77	Diffusion kurtosis imaging in predicting the chemotherapeutic response of colorectal liver metastases: The result of the FDZL-MRinCLM study.. Journal of Clinical Oncology, 2020, 38, e16034-e16034.	1.6	0
78	Impact of cetuximab sequence on progress-free survival (PFS) and overall survival (OS) in patients with RAS wild-type metastatic colorectal cancer (mCRC): A real-world study.. Journal of Clinical Oncology, 2020, 38, e16042-e16042.	1.6	0
79	A phase II study of apatinib treatment for advanced biliary tract carcinoma after failure of the standard chemotherapy.. Journal of Clinical Oncology, 2020, 38, e16684-e16684.	1.6	0